One-shot Sputnik Light vaccine demonstrates 70% efficacy against Delta variant

14 October 2021 | News

Gamaleya Center analysis shows significant efficacy of Sputnik Light vaccine during the first three months after vaccination

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya National Research Center of Epidemiology and Microbiology shared the efficacy of the one-shot Sputnik Light vaccine against infection from the Delta variant of coronavirus.

Gamaleya Center has submitted an article analyzing efficacy of Sputnik Light vaccine against the Delta variant to the medRxiv preprint server for health sciences for publication this week.

Sputnik Light vaccine administered alone has demonstrated 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60. According to reports, Sputnik Light has demonstrated superior efficacy against the Delta variant to less than 50% five months after injection. Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.

The analysis was conducted based on data from 28,000 participants who had received a single dose of Sputnik Light, compared with a control group of 5.6 million individuals who were not vaccinated. The data used in the study was collected in July 2021 in Moscow.

A one-shot vaccination regimen of Sputnik Light has a number of key advantages, including ease of administering the vaccine, monitoring, and a more flexible re-vaccination schedule when used as a booster.

Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization.
The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V – the world’s first registered vaccine against coronavirus. Sputnik Light has been authorized in more than 15 countries with the registration process ongoing in a further 30 countries. Sputnik Light will be produced by RDIF’s international partners in more than 10 countries (India, China, South Korea, Vietnam, Mexico, Argentina, Serbia, Turkey, etc.). This includes the Serum Institute of India, the world’s largest vaccine producer.